Search in:

Advanced search

Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 10

Submit an article Journal homepage

128

Views

CrossRef citations to date

Altmetric

Review

Novel drugs for renal cell carcinoma

Bhanu K Vakkalanka Taussig Cancer Center, Cleveland Clinic Foundation, Department of Solid Tumor Oncology, Cleveland, Ohio 44195, USA +1 216 445 6825; +1 216 444 0114; [email protected]

, MD MRCP FRCR &

Ronald M Bukowski Taussig Cancer Center, Cleveland Clinic Foundation, Department of Solid Tumor Oncology, Cleveland, Ohio 44195, USA +1 216 445 6825; +1 216 444 0114; [email protected]

, MD

Pages 1501-1516 | Published online: 22 Sep 2008

Cite this article
https://doi.org/10.1517/13543784.17.10.1501

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

International Agency for Research on Cancer
Google Scholar
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
PubMed Web of Science ®Google Scholar
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66
PubMed Web of Science ®Google Scholar
Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11(1):37-42
PubMed Web of Science ®Google Scholar
Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991-5004
PubMed Web of Science ®Google Scholar
Clifford SC, Prowse AH, Affara NA, et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22(3):200-9
PubMed Web of Science ®Google Scholar
Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275(33):25733-41
PubMed Web of Science ®Google Scholar
Igarashi H, Esumi M, Ishida H, et al. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002;95(1):47-53
PubMed Web of Science ®Google Scholar
Sulzbacher I, Birner P, Traxler M, et al. Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 2003;120(1):107-12.
PubMed Web of Science ®Google Scholar
Scanga SE, Ruel L, Binari RC, et al. The conserved PI3′K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila. Oncogene 2000;19(35):3971-7
PubMed Web of Science ®Google Scholar
Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008;14(5):1286-90
PubMed Web of Science ®Google Scholar
Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov 2006;5(4):279-80
PubMed Web of Science ®Google Scholar
Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46(7):1116-9
PubMed Web of Science ®Google Scholar
Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13(5):1367-73
PubMed Web of Science ®Google Scholar
Rini BI. Sunitinib. Expert Opin Pharmacother 2007;8(14):2359-69
PubMed Web of Science ®Google Scholar
Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23(5):1028-43
PubMed Web of Science ®Google Scholar
Chouhan JD, Zamarripa DE, Lai PH, et al. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. J Oncol Pharm Pract 2007;13(1):5-15
PubMedGoogle Scholar
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37
PubMed Web of Science ®Google Scholar
Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005;11(16):5827-32
PubMed Web of Science ®Google Scholar
Ikezoe T, Yang Y, Nishioka C, et al. Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Sci 2006;97(9):45-951
PubMed Web of Science ®Google Scholar
Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91(10):4070-6
PubMed Web of Science ®Google Scholar
Patyna S, Laird AD, Mendel DB, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 2006;5(7):1774-82
PubMed Web of Science ®Google Scholar
Anonymous. Sutent-package insert, Pfizer; 2006
Google Scholar
Anonymous. Pfizer product information label; 2007
Google Scholar
Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17(3):353-8
PubMed Web of Science ®Google Scholar
Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
PubMed Web of Science ®Google Scholar
Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105(3):986-93
PubMed Web of Science ®Google Scholar
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16-24
PubMed Web of Science ®Google Scholar
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516-24
PubMed Web of Science ®Google Scholar
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
PubMed Web of Science ®Google Scholar
Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). ASCO annual meeting proceedings [abstrart 5024]. J Clin Oncol 2008;26(Suppl)
Google Scholar
Murphy DA, Makonnen S, Lassoued W, et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006;169(5):1875-85
PubMed Web of Science ®Google Scholar
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
PubMed Web of Science ®Google Scholar
Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
PubMed Web of Science ®Google Scholar
Wilhelm SM, Christopher C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
PubMed Web of Science ®Google Scholar
Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11(15):5472-80
PubMed Web of Science ®Google Scholar
Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92(10):1855-61
PubMed Web of Science ®Google Scholar
Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16(10):1688-94
PubMed Web of Science ®Google Scholar
Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007;13(6):1801-9
PubMed Web of Science ®Google Scholar
Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505-12
PubMed Web of Science ®Google Scholar
Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol25(18S Suppl):5025
Google Scholar
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
PubMed Web of Science ®Google Scholar
Bukowski R, Cella D, Gondek K, et al. Sorafenib TARGETs Clinical Trial Group. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 2007;30(3):220-7
PubMed Web of Science ®Google Scholar
Amato RJ, Harris P, Dalton M, et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). 2007 ASCO Annual Meeting Proceedings Part I. J Clini Oncol 2007;25(18S Suppl):5026
PubMed Web of Science ®Google Scholar
Rini BI, Hutson TE, Elson P, et al. A prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract 346]. 2008 ASCO Genitourinary Cancers Symposium
Google Scholar
Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23(24):5474-83
PubMed Web of Science ®Google Scholar
Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8(11):975-84
PubMed Web of Science ®Google Scholar
Dutcher JP, Wilding G, Hudes GR, et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone [abstract 5127]. J Clin Oncol 2008;26(Suppl)
Google Scholar
Axitinib (AG-013736) as second line therapy for metastatic renal cell cancer: AXIS trial, clinical protocol A4061032, Pfizer
Google Scholar
Wedge SR, Kendrew J, Laurent F, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400
PubMed Web of Science ®Google Scholar
Fiedler W, Mesters R, Heuser M, et al. An open phase I study of cediranib (Recentin, AZD2171) in patients with acute myeloid leukemia (AML) [poster 895]. Am Soc Hematol 2007
Google Scholar
Sridhar SS, MacKenzie MJ, Hotte SJ, et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium [abstract 5047]. J Clin Oncol 2008;26(Suppl)
Google Scholar
Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6(7):2012-21
PubMed Web of Science ®Google Scholar
Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors [abstract 3012]. J Clin Oncol 2005;23:195s
Google Scholar
Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):5031
Google Scholar
Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2(4):296-313
PubMed Web of Science ®Google Scholar
Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001;98(18):10314-9
PubMed Web of Science ®Google Scholar
Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22(12):2336-47
PubMed Web of Science ®Google Scholar
Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-18
PubMed Web of Science ®Google Scholar
Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96
PubMed Web of Science ®Google Scholar
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
PubMed Web of Science ®Google Scholar
Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12(17):5165-73
PubMed Web of Science ®Google Scholar
O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1588-95
PubMed Web of Science ®Google Scholar
Amato RJ, Misellati A, Khan M, et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol2006;24(18S Suppl):4530
Google Scholar
Motzer RJ, Escudier B, Oudard S, et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study [abstr LBA5026]. J Clin Oncol 2008;26(Suppl)
Google Scholar
Melnyk O, Zimmerman M, Kim KJ, et al. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999;161(3):960-3
PubMed Web of Science ®Google Scholar
Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19(3):843-50
PubMed Web of Science ®Google Scholar
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34
PubMed Web of Science ®Google Scholar
Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25(29):4536-41
PubMed Web of Science ®Google Scholar
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-11
PubMed Web of Science ®Google Scholar
Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;19(8):1470-6
PubMed Web of Science ®Google Scholar
Rini BL, Halabi S, Rosenberg JE, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract 350]. 2008 ASCO Genitourinary Cancers Symposium
Google Scholar
Ricart A, Liu G, Tolcher A, et al. A phase I dose-escalation study of anti-α5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors [abstract 166]. Eur J Cancer 2004;2(Suppl):52
Web of Science ®Google Scholar
Figlin RA, Kondagunta GV, Yazji S, et al. Phase II study of volociximab (M200), an α5ß1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC) 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2006;24(18S Suppl):535
Google Scholar
Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol 2006;33(5):534-43
PubMed Web of Science ®Google Scholar
Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26(1):127-31
PubMed Web of Science ®Google Scholar
Golshayan AR, George S, Heng DY, et al. Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy [abstract 5102]. J Clin Oncol 2008:26(20 Suppl)
Google Scholar
Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101(7):1545-51
PubMed Web of Science ®Google Scholar
Dutcher JP, De Souza P, Figlin R, et al. Effect of temsirolimus versus interferon-α on survival of patients with advanced renal cell carcinoma of different tumor histologies [abstract 384]. 2008 ASCO Genitourinary Cancers Symposium
Google Scholar
Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22(1):42-60
PubMed Web of Science ®Google Scholar
Slovin SF, Motzer RJ, Jefferson M, et al. Phase I trial of a PSMA DNA vaccine for patients (pts) with good risk renal cell carcinoma (RCC) [abstract 16073]. J Clin Oncol 2008;26(20 Suppl)
Google Scholar
Johannsen M, Roemer A, Spitaleri G, et al. Phase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in patients with advanced renal cell carcinoma [abstract 16032]. J Clin Oncol 2008;26(Suppl)
Google Scholar
Dupont J, Schwartz L, Koutcher J, et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol22(14S Suppl):3009
Google Scholar
Dupont J, Rothenberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol23(16S Suppl) (Pt I of II):3029
Google Scholar
Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25(22):3288-95
PubMed Web of Science ®Google Scholar
Wood L, Bukowski RM, Dreicer R, et al. Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy [abstract 353]. 2008 ASCO Genitourinary Cancers Symposium
Google Scholar
Rathmell K, Amin C, Wallen E, et al. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC) [abstract 370]. 2008 ASCO Genitourinary Cancers Symposium
Google Scholar
Patel PH, Chadalavada RS, Ishill NM, et al. Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [abstract 5008]. J Clin Oncol 2008;26(Suppl)
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Novel drugs for renal cell carcinoma

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Novel drugs for renal cell carcinoma

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date